Roche Reports Phase 2 Results for Lunsumio in Relapsed/Refractory Follicular Lymphoma

Roche today announced Phase 2 trial results for Lunsumio (mosunetuzumab) in patients with relapsed or refractory follicular lymphoma. The trial demonstrated a complete response rate of 60%, with durable responses observed in patients who achieved complete remission. These results led to FDA accelerated approval of Lunsumio for relapsed/refractory follicular lymphoma.